Skip to content

Identification of key molecules in the brain of PSEN1 pigs to study Alzheimer's Disease

TL;DR

This study demonstrates relevance of the PSEN1 pigs to study AD and suggests necessary refinements to study AD pathogenesis using the PSEN1 pigs.

Abstract

Previously, a clinically relevant swine model (PSEN1ΔE9/+) has been established by utilizing genome editing system to study early onset Alzheimer's Disease (EO-AD). Cognitive assessments and MRI scans of their brain indicate that these pigs carry cognitive deficiencies and abnormal brain physiology, respectively, demonstrating their relevance to study AD. This study was conducted to characterize cell morphology and distributions in the brain cortex and hippocampus of PSEN1ΔE9/+ and wildtype (WT) pigs at 12-14 months of age. First, we quantified the level of APP, Tau, GFAP, and Iba1 proteins in their brain using western blotting. There were no statistically significant differences in Tau and GFAP concentrations in PSEN1 and WT pigs (n=3 per model) but there was a numerical increase in Tau and GFAP in PSEN1 pigs. Next, we examined if the localization of A[beta] and Tau proteins in the brain cortex and hippocampus were different between PSEN1 and WT pigs. Brains from PSEN1 and WT pigs (12-14 months old) were collected, fixed, then immunofluorescent staining was performed to identify Amyloid-beta protein plaques (A[beta]), Tau protein (Tau), reactive microglia (Iba1), astrocytes (GFAP), neurons (NeuN), and nuclei (DAPI) in age-matched PSEN1 and WT brains. PSEN1 pigs had statistically higher Amyloid-beta and Iba1 expression and number of microglia in the cortex than WT pigs. Tau signaling and numbers of neurons were numerically lower in PSEN1 animals than WT. The morphology and cell count of microglia and astrocytes showed early signs of gliosis and pro-inflammatory responses in the brain. The hippocampus analysis did not yield conclusive results, possible due to the animals not being aged long enough. This study demonstrates relevance of the PSEN1 pigs to study AD and suggests necessary refinements to study AD pathogenesis using the PSEN1 pigs.

View source

Similar papers

Aug 2026

Zonisamide Improves Cognitive Impairment and Psychiatric Symptoms related with SAPAP3 in Mouse Models of Alzheimer's Disease.

ZNS exerts neuroprotective effects in 5xFAD mice and improves AD-related cognitive impairment and AD-like lesions, which establishes ZNS as a promising therapeutic avenue for AD and its associated psychiatric symptoms.

Fangtai Yi, Jianfeng Ma, Rui-Yue Zhao et al. · 0 citations
Aug 2026

Correlation analysis between complement proteins and Alzheimer's disease

These findings suggest that microglia may contribute to complement-mediated pathological processes associated with AD, and alterations in their levels may reflect early pathological changes in AD and warrant further investigation.

Ying-Tong Lu, Zi Guo, Meng-Yuan Liu et al. · 0 citations
Jul 2026

STAT3 mediated the isoleucine-induced Alzheimer's disease progression.

Insight is provided into isoleucine as a potential risk factor for AD and STAT3 is identified as a mediator of isoleucine-related AD susceptibility.

Yu Liu, Yuhe Li, Yan-Jun Zhou et al. · 0 citations
Jul 2026

Early treatment with naproxen alters hippocampal metabolites in the TgF344-AD rat model of Alzheimer's disease.

The findings support the use of MRS as a useful non-invasive method of monitoring treatment-related changes in neurochemistry in transgenic animal models and highlight the possibility that earlier naproxen intervention could have distinct neurochemical effects compared to delayed treatment.

Caitlin F. Fowler, Elena Osipyan, Gabriel A. Devenyi et al. · 0 citations
Open access Aug 2026

Intranasal Administration of Isoeugenol Improves Memory Deficits in APP/PS1 Old Mice—A Role Beyond Nrf2 Activation?

Investigating the potential of the skin allergen Isoeugenol to activate Nrf2 and reverse selected AD hallmarks, both in vitro and in vivo, in AD‐specific models reinforces Isoeugenol as a pleiotropic molecule, with great potential for AD treatment.

Ana Silva, Sónia Silva, Jéssica Macedo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.